

Most Read This Week
- Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
- Selective Estrogen Receptor Degrader Elacestrant in ER-Positive, HER2-Negative Advanced Breast Cancer
- Prostate-Only vs Whole-Pelvic Radiation Therapy in High-Risk and Very High–Risk Prostate Cancer
- [177Lu]Lu-PSMA-617 vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer
- ASCO GU 2021: Talazoparib Demonstrates Durable Antitumor Activity in Metastatic Castration-Resistant Prostate Cancer
Recently Updated
- Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer
- Fecal Transplant May Counter Anti-PD-1 Resistance in Melanoma
- Bone Cancer Survivor Selected for SpaceX Flight
- GERD Linked to Squamous Cell Cancers of Larynx, Esophagus
- Lenvatinib Plus Pembrolizumab Tops Sunitinib in Advanced RCC